The case for earlier treatment of HIV infection - PubMed (original) (raw)
Review
. 2004 Dec 1;39(11):1699-704.
doi: 10.1086/425743. Epub 2004 Nov 9.
Affiliations
- PMID: 15578373
- DOI: 10.1086/425743
Review
The case for earlier treatment of HIV infection
Scott D Holmberg et al. Clin Infect Dis. 2004.
Erratum in
- Clin Infect Dis. 2004 Dec 15;39(12):1869
Abstract
Current US guidelines advise that antiretroviral therapy for asymptomatic HIV patients should definitely be started for those who have CD4(+) cell counts of >200 cells/ microL, but antiretroviral therapy is often not started at CD4(+) cell counts much above that level. Guidelines advocating later therapy for HIV infection have been based mainly on sparse and limited cross-sectional data and have been predicated on avoiding drug-related toxicity and viral drug resistance. However, emerging data about factors that contribute to survival and the availability of newer, less toxic drugs are eroding this position. Earlier initiation of antiretroviral therapy--namely, for patients with CD4(+) cell counts of >350 cells/ microL--may, in fact, be associated with lower mortality, better immune improvement, and less drug-related toxicity. These findings coincide with the introduction of antiretroviral drugs that have become more effective and less difficult to take. Earlier initiation of therapy may also reduce HIV transmission, an important public health consideration, and may be beneficial in terms of overall therapeutic cost-effectiveness. Given these accumulating data, we believe reconsideration of the "when-to-start" question is timely and justified.
Comment in
- Antiretroviral therapy: the "when to start" debates.
Cohen CJ, Boyle BA. Cohen CJ, et al. Clin Infect Dis. 2004 Dec 1;39(11):1705-8. doi: 10.1086/425934. Epub 2004 Nov 9. Clin Infect Dis. 2004. PMID: 15578374 Review. No abstract available.
Similar articles
- [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida. Panel de expertos de Gesida y Plan Nacional sobre el Sida. Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Enferm Infecc Microbiol Clin. 2009. PMID: 19246124 Spanish. - HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM. Steingrover R, et al. AIDS. 2008 Aug 20;22(13):1583-8. doi: 10.1097/QAD.0b013e328305bd77. AIDS. 2008. PMID: 18670217 - CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
Moore RD, Keruly JC. Moore RD, et al. Clin Infect Dis. 2007 Feb 1;44(3):441-6. doi: 10.1086/510746. Epub 2006 Dec 20. Clin Infect Dis. 2007. PMID: 17205456 - Patients' preferences regarding the timing of highly active antiretroviral therapy initiation for chronic asymptomatic HIV-1 infection.
Locadia M, van Grieken RA, Prins JM, de Vries HJ, Sprangers MA, Nieuwkerk PT. Locadia M, et al. Antivir Ther. 2006;11(3):335-41. Antivir Ther. 2006. PMID: 16759050 - API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India.
Gupta SB, Pujari SN, Joshi SR, Patel AK; AIDS Society of India Guidelines Development Committee. Gupta SB, et al. J Assoc Physicians India. 2006 Jan;54:57-74. J Assoc Physicians India. 2006. PMID: 16649742 Review.
Cited by
- Reducing False-Positive Results With Fourth-Generation HIV Testing at a Veterans Affairs Medical Center.
Petersen J, Monteiro M, Dalal S, Jhala D. Petersen J, et al. Fed Pract. 2021 May;38(5):232-237. doi: 10.12788/fp.0125. Fed Pract. 2021. PMID: 34177233 Free PMC article. - Factors associated with HIV testing among male injecting drug users: findings from a cross-sectional behavioural and biological survey in Manipur and Nagaland, India.
Ganju D, Ramesh S, Saggurti N. Ganju D, et al. Harm Reduct J. 2016 Jun 21;13(1):21. doi: 10.1186/s12954-016-0110-5. Harm Reduct J. 2016. PMID: 27324253 Free PMC article. - Should expectations about the rate of new antiretroviral drug development impact the timing of HIV treatment initiation and expectations about treatment benefits?
Khademi A, Braithwaite RS, Saure D, Schaefer AJ, Nucifora K, Roberts MS. Khademi A, et al. PLoS One. 2014 Jun 25;9(6):e98354. doi: 10.1371/journal.pone.0098354. eCollection 2014. PLoS One. 2014. PMID: 24963883 Free PMC article. - Dentists' willingness to provide expanded HIV screening in oral health care settings: results from a nationally representative survey.
Pollack HA, Pereyra M, Parish CL, Abel S, Messinger S, Singer R, Kunzel C, Greenberg B, Gerbert B, Glick M, Metsch LR. Pollack HA, et al. Am J Public Health. 2014 May;104(5):872-80. doi: 10.2105/AJPH.2013.301700. Epub 2014 Mar 13. Am J Public Health. 2014. PMID: 24625163 Free PMC article. - Depressive symptoms and antiretroviral therapy (ART) initiation among HIV-infected Russian drinkers.
Goodness TM, Palfai TP, Cheng DM, Coleman SM, Bridden C, Blokhina E, Krupitsky E, Samet JH. Goodness TM, et al. AIDS Behav. 2014 Jun;18(6):1085-93. doi: 10.1007/s10461-013-0674-y. AIDS Behav. 2014. PMID: 24337725 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials